TX-DAVE&BUSTRS/BSTRO-GRP
16.4.2024 15:01:34 CEST | Business Wire | Press release
Dave & Buster's Entertainment, Inc., the ultimate destination for food, drink and entertainment is delighted to announce its latest franchise agreement furthering the brands development in APAC. Dave & Buster’s has finalized a deal to open five new stores in the Philippines, raising the international development store count to 38.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416173901/en/
Antonio Bautista, Chief International Development Officer of Dave & Buster’s and Paul Manuud, President of The Bistro Group (Photo: Business Wire)
Antonio Bautista, Chief International Development Officer at Dave & Buster’s, stated "We are thrilled to announce our expansion into the Philippines, marking another significant milestone in our global growth strategy. Our partnership with The Bistro Group in the Philippines aligns with our mission to deliver exceptional 'Eat, Drink, Play, and Watch' experiences to a broader audience. The Bistro Group's reputation as a trendsetter in the F&B industry in Southeast Asia and beyond makes them an ideal partner for introducing our brand to the Filipino market."
Paul Manuud, President of The Bistro Group remarks, "We were impressed by Dave & Buster’s holistic offering in the hospitality industry where guests can eat, drink, play and watch sports shows all in one location. It is a very good concept that could pioneer well in the Philippines, being poised to be the first of its kind in the local F & B landscape,” expressing enthusiasm for the partnership, he continued, "Entering the 'eatertainment' sector with a renowned brand is an exciting development for us. This collaboration enhances our portfolio, enabling us to offer unparalleled dining and entertainment experiences in the Philippines."
Dave & Buster's has implemented several strategic initiatives to ensure a successful global expansion, including a customizable footprint tailored to meet specific market requirements and the localization of menu offerings with high regional resonance to cater to local preferences and tastes. They have also introduced a proprietary dynamic pricing model to offer flexible pricing options, launched global marketing programs that are demographically agnostic yet locally executable, and implemented a unique amusement strategy and packages to differentiate themselves in the market.
Dave & Buster's is also excited to offer localized entertainment and late-night programming for customers and introduce immersive experiences to enhance customer engagement in the competitive socializing space. With these initiatives, Dave & Buster's is confident they will provide an exceptional experience to their global customers.
About Dave & Buster’s
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 223 venues in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 164 Dave & Buster’s branded stores in 42 states, Puerto Rico, and Canada and offers guests the opportunity to "Eat Drink Play & Watch," all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 59 Main Event branded stores in 20 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. For more information, visit daveandbusters.com.
About The Bistro Group:
Founded in 1994, The Bistro Group is one of the Philippines’ most progressive restaurant chains that popularized the casual dining concept with the entry of TGIFridays in the country almost 30 years ago. Its success led to the launch of other world-class brands such as Italianni’s, Denny’s, Buffalo Wild Wings, Texas Roadhouse, Randy’s Donuts and Hard Rock Café among others as well as Asian concepts like Watami, Modern Shang, Bulgogi Brothers and Fish & Co. The company owns and operates Bistronomia, a collection of boutique Spanish/Mediterranean restaurants, Las Flores, Rambla, Tomatito, BCN by Las Flores and Rumba. Also part of its portfolio is TBG Elite by award-winning corporate executive chef, Josh Boutwood. Its premier restaurants, highlighted by quality ingredients, seasonality and unique cooking methods are Helm, The Test Kitchen, Savage and Ember. The Bistro Group is driven by a people-focused philosophy that is the backbone of its success. Passion and commitment propel its operations…in every restaurant, behind every dish and with every service rendered with generous hospitality.
For restaurant concepts and more information about The Bistro Group, visit https://www.bistro.com.ph/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416173901/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom